The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer [0.03%]
年轻肺癌的基因组学：全面组织基因组分析40岁以下的肺癌患者
Barbara J Gitlitz,Silvia Novello,Tiziana Vavalà et al.
Barbara J Gitlitz et al.
Introduction: Lung adenocarcinomas in young patients (
Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S [0.03%]
对于EGFR G724S的NSCLC患者Afatinib可能是一个潜在的治疗选择
Yang Wei,Benyuan Jiang,Shulin Liu et al.
Yang Wei et al.
Introduction: EGFR G724S has been described to mediate resistance to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs). In vitro experiments have provided compelling evidence that G724S retains sensitivit...
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib [0.03%]
EGFR酪氨酸激酶抑制剂(包括奥希替尼)长期治疗患者中C797S突变的高发生率
Atsushi Osoegawa,Masafumi Yamaguchi,Tomomi Nakamura et al.
Atsushi Osoegawa et al.
Introduction: Although treatment with osimertinib confers survival benefits in patients with lung cancer with the EGFR T790M mutation, the mechanism of acquired resistance to osimertinib remains poorly understood. We cond...
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers [0.03%]
ROS1重排转移性肺癌对免疫检查点抑制作为单一治疗或与化疗联用的反应
Noura J Choudhury,Jaime L Schneider,Tejas Patil et al.
Noura J Choudhury et al.
Introduction: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors...
EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma [0.03%]
EGFR Thr790Leu可能作为对第一代EGFR酪氨酸激酶抑制剂的耐药机制在肺腺癌患者中对Osimertinib有反应
Chan Xiang,Wei Zhang,Li-Wen Xiong et al.
Chan Xiang et al.
Introduction: It has been well established that EGFR Thr790Met is one of the major resistance mechanisms to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). Nevertheless, whether EGFR Thr790Leu (T790L)...
Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study [0.03%]
派姆单抗联合阿霉素用于复发小细胞肺癌患者的治疗：多机构单臂二期研究
Hiroaki Akamatsu,Shunsuke Teraoka,Hidetoshi Hayashi et al.
Hiroaki Akamatsu et al.
Introduction: In patients with relapsed SCLC, amrubicin (AMR) is the current standard treatment in Japan. Nevertheless, its efficacy is not satisfactory and prognosis is poor. Preclinical study suggested that anthracyclin...
Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report [0.03%]
EGFR突变型非小细胞肺癌并发获得性BRAF V600E突变引起脑膜炎使用奥希替尼、达拉菲尼和曲美替尼联合治疗的反应报告一例
Orion Valet,Aurélie Swalduz,Maxime Boussageon et al.
Orion Valet et al.
Molecular sequencing after highly potent targeted gene inhibitors have suggested resistant tumors can display substantial heterogeneity. Among these various mechanisms of resistance, secondary mutations on targetable oncogenes have been ide...
Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma [0.03%]
恶性胸膜间皮瘤患者在真实世界中对接收免疫检查点抑制剂的接受度
Roger Y Kim,Nandita Mitra,Stephen J Bagley et al.
Roger Y Kim et al.
Introduction: Since the July 2017 National Comprehensive Cancer Network (NCCN) malignant pleural mesothelioma (MPM) guideline revision recommended second-line immune checkpoint inhibitors (ICIs), studies have suggested a ...
Exploring the Potential Different Outcomes Associated With the Different Phenotypes Under the Shared Pathologic T3N0 Designation [0.03%]
探讨在相同的共享病理T3N0分类下，不同表型可能产生的不同结果
Terrance Peng,Sean C Wightman,Li Ding et al.
Terrance Peng et al.
Introduction: The objective of this study was to compare overall survival (OS) between patients with pT1-2N1 versus pT3N0 NSCLC and various subtypes of pT3N0 NSCLC. ...
Intracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report [0.03%]
免疫检查点治疗对患有多发性硬化症的非小细胞肺癌患者产生颅内并发症：病例报告
Benjamin Y Lu,Cigdem Isitan,Amit Mahajan et al.
Benjamin Y Lu et al.
Background: Immune checkpoint inhibitors (ICIs) have become an increasingly important tool in cancer treatment, revealing durable responses in several different types of tumors, including NSCLCs. Nevertheless, ICIs carry ...